SOURCE: Equity News Circuit

Equity News Circuit

May 03, 2013 08:20 ET

Free Research Reports on AVEO, CXO, MWW and VRTX Issued by the Paragon Report

Note to Editors: The Following Is an Investment Opinion Being Issued by the EQUITY NEWS CIRCUIT

NEW YORK, NY--(Marketwired - May 3, 2013) - The Paragon Report has released new equity reports today. As a leading provider of free in depth reports and timely market updates, Bedford is an essential resource for hundreds of thousands of investors across the country.

AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) shares plunged nearly 50 percent on more than six times the average daily volume Thursday. The company recently announced that an FDA advisory panel has voted 13-1 against the company's kidney cancer drug, tivozanib.

Find out more about AVEO Pharmaceuticals including full access to the free equity report at: www.ParagonReport.com/AVEO

Concho Resources Inc. (NYSE: CXO) shares declined 4.30 percent on more than 3.5 times the average daily volume Thursday to close at $80.14 a share. The company reported a net income of $30.1 million, or $0.29 per diluted share, for the first quarter of 2013, a decrease of 3.3 percent when compared to the year ago quarter.

Find out more about Concho Resources including full access to the free equity report at: www.ParagonReport.com/CXO

Monster Worldwide, Inc. (NYSE: MWW) shares surged over 10.0 percent on more than double the average daily volume Thursday. The company reported a net income of $5.0 million for the first quarter of 2013, an increase of roughly 33 percent when compared to a net income of $3.7 million in the year ago quarter.

Find out more about Monster Worldwide including full access to the free equity report at: www.ParagonReport.com/MWW

Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) shares have gained approximately 85 percent year-to-date. The company announced sales for their cystic fibrosis drug Kalydeco totaled $61.8 million for the first quarter of 2013, an increase from $58.5 million posted in the preceding quarter. The company now expects full year sales of Kalydeco to total $300 million to $340 million, up from their previous guidance of $280 million to $320 million.

Find out more about Vertex Pharmaceuticals including full access to the free equity report at: www.ParagonReport.com/VRTX

Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. A third party, Providence Media Strategies LLC has paid Equity News Circuit five hundred dollars for the publication of this news release. Neither Equity News Circuit, nor the hiring party, has a financial relationship with any company whose stock is mentioned in this release. Neither Equity News Circuit nor the hiring party are a registered investment advisor, and nothing in this report is intended as a solicitation to buy or sell any security.

Contact Information